1. Home
  2. GSRT vs OLMA Comparison

GSRT vs OLMA Comparison

Compare GSRT & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GSRT
  • OLMA
  • Stock Information
  • Founded
  • GSRT 2023
  • OLMA 2006
  • Country
  • GSRT United States
  • OLMA United States
  • Employees
  • GSRT N/A
  • OLMA N/A
  • Industry
  • GSRT
  • OLMA Biotechnology: Pharmaceutical Preparations
  • Sector
  • GSRT
  • OLMA Health Care
  • Exchange
  • GSRT Nasdaq
  • OLMA Nasdaq
  • Market Cap
  • GSRT 302.2M
  • OLMA 378.9M
  • IPO Year
  • GSRT 2024
  • OLMA 2020
  • Fundamental
  • Price
  • GSRT $10.37
  • OLMA $5.46
  • Analyst Decision
  • GSRT Strong Buy
  • OLMA Strong Buy
  • Analyst Count
  • GSRT 1
  • OLMA 5
  • Target Price
  • GSRT $19.00
  • OLMA $24.00
  • AVG Volume (30 Days)
  • GSRT 518.2K
  • OLMA 450.7K
  • Earning Date
  • GSRT 01-01-0001
  • OLMA 08-11-2025
  • Dividend Yield
  • GSRT N/A
  • OLMA N/A
  • EPS Growth
  • GSRT N/A
  • OLMA N/A
  • EPS
  • GSRT 0.19
  • OLMA N/A
  • Revenue
  • GSRT N/A
  • OLMA N/A
  • Revenue This Year
  • GSRT N/A
  • OLMA N/A
  • Revenue Next Year
  • GSRT N/A
  • OLMA N/A
  • P/E Ratio
  • GSRT $53.45
  • OLMA N/A
  • Revenue Growth
  • GSRT N/A
  • OLMA N/A
  • 52 Week Low
  • GSRT $9.86
  • OLMA $2.86
  • 52 Week High
  • GSRT $11.49
  • OLMA $13.93
  • Technical
  • Relative Strength Index (RSI)
  • GSRT 40.74
  • OLMA 54.42
  • Support Level
  • GSRT $10.36
  • OLMA $5.54
  • Resistance Level
  • GSRT $10.40
  • OLMA $5.85
  • Average True Range (ATR)
  • GSRT 0.08
  • OLMA 0.30
  • MACD
  • GSRT 0.01
  • OLMA -0.01
  • Stochastic Oscillator
  • GSRT 14.67
  • OLMA 51.79

About GSRT GSR III Acquisition Corp. Ordinary Shares

GSR III Acquisition Corp is a blank check company.

About OLMA Olema Pharmaceuticals Inc.

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

Share on Social Networks: